Cargando…

Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis

BACKGROUND: The E75 and GP2 vaccines are the few therapeutic vaccines targeting HER2 currently under clinical research for patients with breast cancer. METHODS: Databases, including the Cochrane Library, PubMed, Medline, Embase, and Web of Science, were used to retrieve clinical studies on E75 and G...

Descripción completa

Detalles Bibliográficos
Autores principales:	You, Zicong, Zhou, Weijun, Weng, Junyan, Feng, Haizhan, Liang, Peiqiao, Li, Yuhua, Shi, Fujun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442296/ https://www.ncbi.nlm.nih.gov/pubmed/34526020 http://dx.doi.org/10.1186/s12935-021-02187-1

Ejemplares similares

Sphingomyelin synthase 2 promotes an aggressive breast cancer phenotype by disrupting the homoeostasis of ceramide and sphingomyelin
por: Zheng, Kehong, et al.
Publicado: (2019)

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis
por: Chen, Shanshan, et al.
Publicado: (2019)

Vaccination against Her-2/neu, with focus on peptide-based vaccines
por: Tobias, J., et al.
Publicado: (2022)

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC)
por: Overholser, Jay, et al.
Publicado: (2015)

Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics
por: Cavallaro, Palmira Alessia, et al.
Publicado: (2023)

Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer
por: Shao, Nan, et al.
Publicado: (2019)

Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review
por: Wang, Chaokun, et al.
Publicado: (2020)

DRB1*11 allele expression and HER2 pre-existing immunity may predict benefit in breast cancer patients vaccinated with the HER2 modified AE37 peptide vaccine
por: Anastasopoulou, Eleftheria A, et al.
Publicado: (2015)

Key Genes and Prognostic Analysis in HER2+ Breast Cancer
por: Weng, Yujie, et al.
Publicado: (2021)

Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition
por: Correa, Isabel, et al.
Publicado: (2001)

Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis
por: He, Lin, et al.
Publicado: (2019)

Rotaxane nanomachines in future molecular electronics
por: Wu, Peiqiao, et al.
Publicado: (2022)

HER2 Targeting Peptides Screening and Applications in Tumor Imaging and Drug Delivery
por: Geng, Lingling, et al.
Publicado: (2016)

Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer
por: You, Yiwen, et al.
Publicado: (2018)

Neoadjuvant Treatment with HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
por: Gunasekara, Agampodi Danushi M., et al.
Publicado: (2022)

Optimization of a Method to Prepare Liposomes Containing HER2/Neu- Derived Peptide as a Vaccine Delivery System for Breast Cancer
por: Shariat, Sheyda, et al.
Publicado: (2014)

Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model
por: Razazan, Atefeh, et al.
Publicado: (2017)

HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment
por: Wang, Mengting, et al.
Publicado: (2022)

Freund's vaccine adjuvant promotes Her2/Neu breast cancer
por: Cotroneo, Michelle S, et al.
Publicado: (2009)

Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model
por: Tobias, Joshua, et al.
Publicado: (2022)

A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2(+) breast cancer
por: Costa, Ricardo, et al.
Publicado: (2019)

Phospholipid translocation captured in a bifunctional membrane protein MprF
por: Song, Danfeng, et al.
Publicado: (2021)

miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance
por: Lin, Jiansheng, et al.
Publicado: (2022)

Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis
por: Hu, Wenyu, et al.
Publicado: (2023)

Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis
por: Yu, Qiuyan, et al.
Publicado: (2015)

HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis
por: Xu, Qian-Qian, et al.
Publicado: (2016)

The volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI: association with prognostic factors in HER2-positive breast cancer
por: You, Chao, et al.
Publicado: (2019)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

Efficacy and Safety of Anti-HER2 Agents in Combination With Chemotherapy for Metastatic HER2-Positive Breast Cancer Patient: A Network Meta-Analysis
por: Zhang, Xiaohui, et al.
Publicado: (2021)

Theranostic application of miR-429 in HER2+ breast cancer
por: Cava, Claudia, et al.
Publicado: (2020)

Effects of HER2 status on the prognosis of male breast cancer: a population-based study
por: Chen, Liang, et al.
Publicado: (2019)

Vaccination in Spain and Her Colonies
Publicado: (1870)

Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis
por: Wei, Tong, et al.
Publicado: (2023)

HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development
por: Arab, Atefeh, et al.
Publicado: (2020)

Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer
por: Pallerla, Sandeep, et al.
Publicado: (2021)

HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Correlation of HER2, p95HER2 and HER3 Expression and Treatment Outcome of Lapatinib plus Capecitabine in her2-Positive Metastatic Breast Cancer
por: Han, Sae-Won, et al.
Publicado: (2012)

HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor
por: Liu, Yuanyuan, et al.
Publicado: (2019)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
por: Majumder, Avisek, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_djvtibdfqfglsq1irq2itbfugm